91 related articles for article (PubMed ID: 6595923)
1. Toward the use of monoclonal antibodies in the analysis of tumor progression and cellular heterogeneity of human breast cancer.
Nilsson K
Acta Chir Scand Suppl; 1984; 519():15-8. PubMed ID: 6595923
[TBL] [Abstract][Full Text] [Related]
2. Definition of antigenic heterogeneity and modulation among human mammary carcinoma cell populations using monoclonal antibodies to tumor-associated antigens.
Hand PH; Nuti M; Colcher D; Schlom J
Cancer Res; 1983 Feb; 43(2):728-35. PubMed ID: 6848188
[TBL] [Abstract][Full Text] [Related]
3. Genome-wide search for loss of heterozygosity using laser capture microdissected tissue of breast carcinoma: an implication for mutator phenotype and breast cancer pathogenesis.
Shen CY; Yu JC; Lo YL; Kuo CH; Yue CT; Jou YS; Huang CS; Lung JC; Wu CW
Cancer Res; 2000 Jul; 60(14):3884-92. PubMed ID: 10919664
[TBL] [Abstract][Full Text] [Related]
4. [Cloning of anti-breast cancer monoclonal antibodies from phage antibody libraries].
Zhang G; Wang Y; Wang Y
Zhonghua Zhong Liu Za Zhi; 1995 Jul; 17(4):258-62. PubMed ID: 7587890
[TBL] [Abstract][Full Text] [Related]
5. Apoptosis in breast carcinomas detected with monoclonal antibody to single-stranded DNA: relation to bcl-2 expression, hormone receptors, and lymph node metastases.
Frankfurt OS; Robb JA; Sugarbaker EV; Villa L
Clin Cancer Res; 1997 Mar; 3(3):465-71. PubMed ID: 9815706
[TBL] [Abstract][Full Text] [Related]
6. Correlations among p53, Her-2/neu, and ras overexpression and aneuploidy by multiparameter flow cytometry in human breast cancer: evidence for a common phenotypic evolutionary pattern in infiltrating ductal carcinomas.
Smith CA; Pollice AA; Gu LP; Brown KA; Singh SG; Janocko LE; Johnson R; Julian T; Hyams D; Wolmark N; Sweeney L; Silverman JF; Shackney SE
Clin Cancer Res; 2000 Jan; 6(1):112-26. PubMed ID: 10656439
[TBL] [Abstract][Full Text] [Related]
7. Mutant p53 expression and DNA analysis in human breast cancer comparison with conventional clinicopathological parameters.
Rosanelli GP; Steindorfer P; Wirnsberger GH; Klimpfinger M; Ratschek M; Puerstner P; Auner H; Berhold A
Anticancer Res; 1995; 15(2):581-6. PubMed ID: 7763041
[TBL] [Abstract][Full Text] [Related]
8. Characterization of a monoclonal antibody to human breast cancer cells.
Hendler FJ; Yuan D; Vitetta ES
Trans Assoc Am Physicians; 1981; 94():217-24. PubMed ID: 7344221
[No Abstract] [Full Text] [Related]
9. Hormone-resistant breast cancer or "feeding the hand that bites you".
Horwitz KB
Prog Clin Biol Res; 1994; 387():29-45. PubMed ID: 7972253
[TBL] [Abstract][Full Text] [Related]
10. Prognostic indicators including DNA histogram type, receptor content, and staging related to human breast cancer patient survival.
Coulson PB; Thornthwaite JT; Woolley TW; Sugarbaker EV; Seckinger D
Cancer Res; 1984 Sep; 44(9):4187-96. PubMed ID: 6744328
[TBL] [Abstract][Full Text] [Related]
11. [Immunohistochemical evaluation of several tumor markers (CEA, ferritin, Ca) and their correlation with estro-progestin receptor state in neoplasms].
Forti E; Wolf D; Melia M
Pathologica; 1985; 77(1049):241-9. PubMed ID: 3913892
[No Abstract] [Full Text] [Related]
12. [Use of immunohistochemical markers in the diagnosis of carcinoma of the breast].
Bussolati G
Minerva Chir; 1988 Sep; 43(18 Suppl):5-7. PubMed ID: 3226595
[No Abstract] [Full Text] [Related]
13. Use of antibodies against estrogen and progesterone receptors to identify metastatic breast and ovarian carcinomas by conventional immunohistochemical and tyramide signal amplification methods.
Kaufmann O; Köther S; Dietel M
Mod Pathol; 1998 Apr; 11(4):357-63. PubMed ID: 9578086
[TBL] [Abstract][Full Text] [Related]
14. Genetic heterogeneity and clonal evolution underlying development of asynchronous metastasis in human breast cancer.
Kuukasjärvi T; Karhu R; Tanner M; Kähkönen M; Schäffer A; Nupponen N; Pennanen S; Kallioniemi A; Kallioniemi OP; Isola J
Cancer Res; 1997 Apr; 57(8):1597-604. PubMed ID: 9108466
[TBL] [Abstract][Full Text] [Related]
15. Production of anti-tumor human monoclonal antibodies using different approaches.
Liu H; Xu ZL; Wang Y; Yang L; Feng O; Li Y; Wang YM; Zhang GG
Hum Antibodies Hybridomas; 1993 Jan; 4(1):2-8. PubMed ID: 8381684
[TBL] [Abstract][Full Text] [Related]
16. Breast cancer heterogeneity assessed by flow cytometry.
Savarese A; Vecchione A
In Vivo; 1993; 7(6B):631-4. PubMed ID: 8193285
[TBL] [Abstract][Full Text] [Related]
17. Rabbit monoclonal antibodies show higher sensitivity than mouse monoclonals for estrogen and progesterone receptor evaluation in breast cancer by immunohistochemistry.
Rocha R; Nunes C; Rocha G; Oliveira F; Sanches F; Gobbi H
Pathol Res Pract; 2008; 204(9):655-62. PubMed ID: 18565685
[TBL] [Abstract][Full Text] [Related]
18. Breast carcinoma in pregnant women: assessment of clinicopathologic and immunohistochemical features.
Middleton LP; Amin M; Gwyn K; Theriault R; Sahin A
Cancer; 2003 Sep; 98(5):1055-60. PubMed ID: 12942575
[TBL] [Abstract][Full Text] [Related]
19. Contrasting expression of thrombospondin-1 and osteopontin correlates with absence or presence of metastatic phenotype in an isogenic model of spontaneous human breast cancer metastasis.
Urquidi V; Sloan D; Kawai K; Agarwal D; Woodman AC; Tarin D; Goodison S
Clin Cancer Res; 2002 Jan; 8(1):61-74. PubMed ID: 11801541
[TBL] [Abstract][Full Text] [Related]
20. Detection of a Mr 24,000 estrogen-regulated protein in human breast cancer by monoclonal antibodies.
Adams DJ; Hajj H; Edwards DP; Bjercke RJ; McGuire WL
Cancer Res; 1983 Sep; 43(9):4297-301. PubMed ID: 6871865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
